Insights From Technical Analysis
Is Neuren Pharmaceuticals (ASX: NEU) Poised to Reclaim Higher Levels After Forming a Higher Low?
Neuren Pharmaceuticals (ASX: NEU) is a rare-disease biotech generating revenue from DAYBUE while advancing NNZ-2591. After declines from regulatory and guidance setbacks, improving US rollout and technical strength suggest a recovery, with the stock forming higher lows and testing key resistance levels.
Marmota (ASX: MEU) Share Price Surges as Traders Chase Momentum in South Australia Gold Play
Marmota (ASX: MEU) has surged back into focus after strong gains driven by high-grade drilling results from its Greenewood gold project in South Australia. Renewed exploration activity, rising gold prices, and aggressive drilling have boosted investor interest. The stock remains highly speculative but increasingly watched by ASX momentum traders.
Has Neurizon Therapeutics (ASX: NUZ) Formed a Sustainable Long-Term Floor at Its Multi-Year Support Base?
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
Haranga Resources (ASX: HAR) Rockets Higher as Gold Discovery Frenzy Ignites Massive Share Price Volatility
Haranga Resources has seen sharp volatility driven by renewed excitement around its Lincoln Gold Project in the US, with drilling results and expected JORC resource updates fueling speculation. The company remains an early-stage explorer, heavily dependent on exploration success, making its share price highly sensitive to news flow and gold sentiment.
Minbos Resources (ASX: MNB) Explodes Higher as Funding Breakthrough Sparks Massive Share Price Surge
Minbos Resources surged after securing US$21.5 m+ in debt funding for its Cabinda Phosphate Project in Angola, boosting investor confidence in its move toward production. The market now eyes construction progress, though execution, funding, and ramp-up risks remain significant.
Is Elevra Lithium (ASX: ELV) Ready to Break Through Key Resistance?
Elevra Lithium (ASX: ELV) is a dual-listed North American-focused producer with growth assets, led by its Québec NAL operation. Recent share moves reflect capital raising, record production, index inclusion, improving lithium sentiment, while technicals show an uptrend nearing key resistance.